Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the effectiveness of bortezomib (Velcade)
plus prednisone for treating chronic graft versus host disease (cGVHD) and the safety of this
drug combination in this patient population. Chronic GVHD is a medical condition that may
occur after allogeneic stem cell transplantation. The donor's immune system may recognize the
participants body (the host) as foreign and attempt to "reject" it. Bortezomib has been used
in other research studies, and information from those studies suggests that this drug may
help to control the abnormal immune responses that underlie cGVHD.